Antipsychotic Treatment of 22q11.2 Deletion Syndrome-Related Psychoses

Abstract

In the recent study by Verhoeven and Egger, 2015 and the recent letter to the editor by Boot et al. 2015 an emphasis is given to the best possible pharmacological treatment of 22q11-2 Deletion-Syndrome related psychoses. We would like to present the case of a 23-year old Cypriot patient with 22q11.2 deletion syndrome who fulfilled criteria for treatment resistant schizophrenia (TRS). He was sequentially treated with aripiprazole, risperidone, olanzapine, haloperidol and a combination treatment with olanzapine and haloperidol. Clozapine was the only antipsychotic medication that has improved his condition.

• References

• 1 Verhoeven WM, Egger JI. Atypical Antipsychotics and Relapsing Psychoses in 22q11.2 Deletion Syndrome: A Long-term Evaluation of 28 Patients. Pharmacopsychiatry 2015; 48: 104-110
• 2 Boot E, Butcher NJ, Vorstman JA. et al. Pharmacological treatment of 22q11.2 deletion syndrome-related psychoses. Pharmacopsychiatry 2015; 48: 219-220
• 3 Eliez S, Antonarakis SE, Morris MA. et al. Prenatal origin of the deletion 22q11.2 and brain development in velocardiofacial syndrome. Arch Gen Psychiatry 2001; 58: 64-68
• 4 Kane J, Hognifeld G, Singer J. et al. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988; 45: 789-796
• 5 Hasan Alkomiet, Falkai Peter, Wobrock Thomas. et al. World Federation of Societies of Biological Psychiatry Guidelines for Biological Treatment of Schizophrenia, Update 2012 on the acute treatment of schizophrenia and the management of treatment resistance. World J Biol Psychiatry 2012 13: 318-378
• 6 Woods SW. Chlorpromazine equivalent doses for the newer atypical antipsychotics. J Clin Psychiatry 2003; 64: 663-667
• 7 Butcher NJ, Fung WL, Fitzpatrick L. et al. Response to clozapine in a clinically identifiable subtype of schizophrenia. Br J Psychiatry 2015; 206: 484-491